This Phase 2b study, run under Lilly’s chronic weight management master protocol (NCT06143956), examines the weight-lowering effect and safety of macupatide plus eloralintide compared with placebo in adults with obesity or overweight and without type 2 diabetes. Participation lasts about 64 weeks. It runs at 40 sites in the United States. The registry lists exclusions for a history of bradyarrhythmia or sinus bradycardia, a resting pulse above 100 or below 60 bpm, and a history of pancreatitis.
Read with care: A registry record describes a study’s plan and status. It is not a result, and it does not show that the drug works or is safe.
Study context
What the study tests
This Phase 2b study tests macupatide and eloralintide, alone or in combination, against placebo, double-blind, in adults with obesity or overweight who do not have type 2 diabetes. It runs under the chronic weight management master protocol (NCT06143956). The primary endpoint is percent change in body weight from baseline to week 36, with week 48 as a secondary measure. The record lists 400 participants and about 64 weeks of participation.
Who can take part
Adults aged 18 to 75 meet the master protocol entry criteria. The study adds exclusions for type 1 or type 2 diabetes, a history of pancreatitis, a history of bradyarrhythmia or sinus bradycardia, and a resting pulse above 100 or below 60 beats per minute. All 40 listed sites are in the United States.
What the registry does not say
No results are posted. Secondary measures include the share of participants losing at least 5% and at least 10% of body weight at week 36; these are planned measures, not findings. Primary completion is registered for September 2027.
Source: ClinicalTrials.gov record NCT07589608, read on 2026-10-15. Registered plans can change.